ProPhase Labs, Inc.

PRPH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-3.1M $-5.2M $-7.4M $-6.8M $-4.5M $4.0M $-34.4M $-6.6M
Depreciation & Amortization $623.0K $962.0K $1.6M $698.0K $1.0M $1.5M $1.5M $1.5M
Depreciation — — — $400.0K $700.0K — — $1.9M
Amortization $0 $600.0K $800.0K $600.0K $600.0K $600.0K $800.0K $600.0K
Stock-Based Compensation $375.0K $390.0K $433.0K $431.0K $508.0K $521.0K $617.0K $636.0K
Net Cash from Operating Activities $-78.0K $-748.0K $-1.2M $-3.5M $-247.0K $-3.4M $-3.5M $-4.0M
Investing Activities
Capital Expenditures — — $0 $0 $0 $0 $40.0K $-1.0K
Business Acquisitions — — — — — — $0 $0
Net Cash from Investing Activities $0 $12.0K $0 $0 $67.0K $853.0K $-40.0K $-97.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — $0 $0
Net Cash from Financing Activities $67.0K $677.0K $915.0K $3.7M $261.0K $1.9M $3.7M $2.9M
Net Change in Cash $-11.0K $-59.0K $-315.0K $236.0K $81.0K $-590.0K $177.0K $-1.3M
Free Cash Flow — — $-1.2M $-3.5M $-247.0K $-3.4M $-3.6M $-4.0M
← Newer Page 1 of 8 Older →